

मिसिल स.- 8(137)/2025/डी.पी/एनपीपीए-डीवी-II

F. No. 8(137)/2025/DP/NPPA-Div. II

कार्यवाही स. : 269/137/2025/F

Proceeding No: 269/137/2025/F

Minutes of the 269th (overall) and 137th meeting of the Authority under DPCO, 2013 held on 15.09.2025 at 12:30 PM

The 269th meeting of the Authority (overall), which is the 137th meeting under the DPCO, 2013 was held on 15th September, 2025 at 12:30 PM under the Chairmanship of Shri P. Krishnamurthy, Chairman, NPPA. The following Authority members were present during the meeting:

- (i) Ms. Sai Ahlladini Panda, Member Secretary, NPPA
- (ii) Shri Manmohan Sachdeva, Additional Chief Adviser Cost (ACAC), O/o Chief Adviser (Cost), Department of Expenditure
- (iii) Dr. Rose Mary K. Abraham, Economic Advisor, Department of Economic Affairs

Shri Ranga Chandrashekar, Joint Drug Controller, CDSCO, Ministry of Health & Family Welfare.

The following officers of NPPA attended the meeting and assisted the Authority in its deliberations:

- (i) Sh. Sanjay Kumar, Advisor (Cost)
- (ii) Ms. Rashmi Tahiliani, Director (Pricing)
- (iii) Sh. Mahaveer Saini, Deputy Director (Pricing)
- (iv) Ms. Yuvika Panwar, Assistant Director (Pricing)
- (v) Sh. Bhiva Ram Yadav, Assistant Director (Overcharging)
- (vi) Sh. Mayur Panwar, Assistant Director (Pricing)

1. Agenda item no. 1 - Confirmation of Minutes of the 136th Meeting held on 28.08.2025.

1.1 The Authority confirmed the minutes of the meeting without any change.

2. Agenda item no. 2 – (a) Action Taken Report (ATR) on decisions taken by NPPA in its 136th Meeting held on 28.08.2025.

2.1 Noted.

3. Agenda item no. 3 – Status of New Drug applications

3.1 Noted.

4. Agenda item no. 4 – New Drug applications for Price fixation under Para 5 and Para 15 of DPCO, 2013

4.1 The Authority deliberated on 9 (nine) cases of retail price fixation of new drugs as presented in Agenda no. 4 (1) to 4 (9) falling under the purview of Para 2(1)(u) of DPCO, 2013. The Authority approved the retail prices of 9 (nine) new drugs under Para 5 and 15 of the DPCO 2013 as given in **Table 1 below.**

Table No. 1: Retail price fixation of new drugs

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1	4(1)	Aceclofenac, Paracetamol & Thiocolchicoside Tablets	Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Thiocolchicoside IP 8 mg	1 Tablet	M/s Innova Captab Ltd./ M/s Macleods Pharmaceuticals Ltd.	27.49
2	4(2)	Aceclofenac, Paracetamol & Thiocolchicoside Tablets	Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Thiocolchicoside IP 4 mg	1 Tablet	M/s Innova Captab Ltd./ M/s Macleods Pharmaceuticals Ltd.	18.43
3	4(3)	Ibuprofen & Paracetamol suspension	Each 5 ml contains: Ibuprofen IP 100 mg Paracetamol IP 162.5 mg	1 ml	M/s Shiva Biogenetic Pharmaceuticals Pvt. Ltd./ M/s Mankind Prime Labs Pvt. Ltd.	0.55
4	4(4)	Dapagliflozin, Glimepiride & Metformin Hydrochloride (ER) Tablets	Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP equivalent to Dapagliflozin 10 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg (as extended release)	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Blue Cross Laboratories Pvt. Ltd.	10.80
5	4(5)	Dapagliflozin, Glimepiride & Metformin	Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd./	11.70

S. No.	Agenda No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
		Hydrochloride (ER) Tablets	equivalent to Dapagliflozin 10 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg (as extended release)		M/s Blue Cross Laboratories Pvt. Ltd.	
6	4(6)	Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 1 mg, Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Alembic Pharmaceuticals Ltd.	13.24
7	4(7)	Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets	Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg, Glimepiride IP 2 mg, Metformin Hydrochloride IP 500 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Alembic Pharmaceuticals Ltd.	15.00
8	4(8)	Sitagliptin, Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Macleods Pharmaceuticals Ltd.	30.00
9	4(9)	Sitagliptin, Empagliflozin & Metformin Hydrochloride (ER) Tablets	Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Empagliflozin 25 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg	1 Tablet	M/s Exemed Pharmaceuticals/ M/s Macleods Pharmaceuticals Ltd.	34.50


5. Agenda item no. 5: Ceiling Prices of Orthopaedic Knee Implants for Knee Replacement System.

5.1 The Authority noted that the ceiling prices of the Orthopaedic Knee Implants for Knee Replacement System were last notified vide notification S.O. 3869(E) dated 10 September, 2024 and it is in force up to 15 September, 2025.

5.2 The Authority was briefed that representations received from manufacturers and the industry associations are under its consideration.

5.3 Accordingly, the Authority, decided to extend the period for which the notification number S.O. 3869(E), dated the 10th September, 2024 shall be in force in respect of Orthopaedic Knee Implants for Knee Replacement System for a further period of up to two months beyond the 15th September, 2025, i.e., up to the 15th November, 2025, unless amended by a subsequent notification.

The meeting ended with a vote of thanks to the Chair and all the participants in the meeting.


(Sai Ahladini Panda)
Member Secretary